International Journal of Innovative Technologies in Social Science

e-ISSN: 2544-9435

Operating Publisher
SciFormat Publishing Inc.
ISNI: 0000 0005 1449 8214

2734 17 Avenue SW,
Calgary, Alberta, T3E0A7,
Canada
+15878858911
editorial-office@sciformat.ca

ARTICLE TITLE	GUANFACINE MECHANISMS, CLINICAL EFFICACY, AND ROLE IN MODERN ADHD PHARMACOTHERAPY – A REVIEW
DOI	https://doi.org/10.31435/ijitss.2(50).2026.5491
RECEIVED	14 February 2026
ACCEPTED	27 May 2026
PUBLISHED	08 June 2026
LICENSE	The article is licensed under a **Creative Commons Attribution 4.0 International License.**

GUANFACINE MECHANISMS, CLINICAL EFFICACY, AND ROLE IN MODERN ADHD PHARMACOTHERAPY – A REVIEW

Wiktoria Bojarska *(Corresponding Author, Email: vbojarska002@gmail.com)*
University Clinical Hospital No. 4 in Lublin, ul. Doktora Kazimierza Jaczewskiego 8, 20-090 Lublin, Poland
ORCID ID: 0009-0008-6923-2068

Agnieszka Barbara Białek
Medical University of Lublin, Faculty of Medicine, ul. Witolda Chodźki 19, 20-093 Lublin, Poland
ORCID ID: 0009-0004-0855-7732

Radosław Januszczak
University Clinical Hospital No. 4 in Lublin, ul. Doktora Kazimierza Jaczewskiego 8, 20-090 Lublin, Poland
ORCID ID: 0009-0007-4088-8138

Gabriela Anna Gilarska
Medical University of Lublin, Faculty of Medicine, ul. Witolda Chodźki 19, 20-093 Lublin, Poland
ORCID ID: 0009-0004-4818-8070

Julianna Cholewa
Human Anatomy Research Group, Medical University of Lublin, Jaczewskiego 4, 20-400, Lublin, Poland
ORCID ID: 0009-0007-2432-1828

Sylwia Bojarska
Cognitive Institute - Cognitive-Behavioural Psychotherapy School, ul. Bonerowska 2/5, 31-030 Kraków, Poland
ORCID ID: 0009-0006-1277-8452

Maja Sygacz
University Clinical Hospital No. 4 in Lublin, ul. Doktora Kazimierza Jaczewskiego 8, 20-090 Lublin, Poland
ORCID ID: 0009-0006-8689-8975

ABSTRACT

Attention-deficit/hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder worldwide. It affects cognitive, behavioural, and social functioning across the lifespan. Symptoms such as inattention, hyperactivity, and impulsivity can significantly impair academic, occupational, and interpersonal outcomes. Stimulant medications, including methylphenidate and amphetamine derivatives, remain the first-line treatment due to their robust efficacy. However, their use is often limited by side effects, risk of misuse, and incomplete response in a substantial subset of patients. These limitations have driven growing interest in non-stimulant pharmacotherapies that target alternative neurobiological mechanisms.

Guanfacine, a selective alpha-2A adrenergic receptor agonist, has emerged as a promising non-stimulant option. By enhancing prefrontal cortex signalling through alpha-2A receptor agonism, guanfacine stabilises neuronal firing, which improves working memory, attention regulation, and inhibitory control. Clinical studies indicate that guanfacine is particularly effective in reducing hyperactivity and impulsivity and can serve as an adjunctive therapy in patients with partial stimulant response. Its sedative effects may also provide additional benefits for comorbid sleep disturbances and anxiety, while its non-stimulant profile lowers the risk of abuse.

Common adverse effects include sedation, hypotension, and bradycardia, necessitating careful dose titration and monitoring. Evidence regarding long-term efficacy and safety, particularly in adults, remains limited, emphasising the need for further research to optimise individualised treatment strategies. Nonetheless, guanfacine represents an important addition to ADHD pharmacotherapy, offering clinicians a valuable tool to tailor interventions according to patient-specific symptom profiles and treatment goals.

KEYWORDS

ADHD, Guanfacine, Alpha-2A Adrenergic Receptor, Non-Stimulant Treatment, ADHD Pharmacotherapy

CITATION

Wiktoria Bojarska, Agnieszka Barbara Białek, Radosław Januszczak, Gabriela Anna Gilarska, Julianna Cholewa, Sylwia Bojarska, Maja Sygacz. (2026) Guanfacine Mechanisms, Clinical Efficacy, and Role in Modern ADHD Pharmacotherapy – A Review. *International Journal of Innovative Technologies in Social Science*. 2(50). doi: 10.31435/ijitss.2(50).2026.5491

Introduction

Attention-deficit/hyperactivity disorder (ADHD) affects approximately 7.2% of children and 2.5% of adults worldwide, making it the most prevalent neurodevelopmental disorder (American Psychiatric Association, 2022; Mechler et al., 2022; Noah & Sedky, 2025). ADHD is characterised by persistent patterns of inattention, hyperactivity, and impulsivity, which are developmentally inappropriate and cause clinically significant impairment in multiple functional domains, including academic achievement, occupational performance, and interpersonal relationships (American Psychiatric Association, 2022; Noah & Sedky, 2025). The disorder has profound long-term consequences, including increased risk for mental health disorders, substance use, and difficulties in achieving social and occupational stability (Faraone et al., 2015; Taipale et al., 2024).

Diagnosis is guided by criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), which requires symptoms to persist for at least six months, appear before age 12, and occur across multiple settings (American Psychiatric Association, 2022). Inattention manifests as difficulties in sustaining attention, organising tasks, and following through on instructions, whereas hyperactivity and impulsivity involve excessive motor activity, restlessness, and hasty decision-making. These symptom domains reflect underlying deficits in executive function, including working memory, inhibitory control, and cognitive flexibility (Petrovic & Castellanos, 2016).

Neurobiologically, ADHD is associated with dysfunction in frontostriatal and frontoparietal networks, with particular involvement of the prefrontal cortex (PFC), which governs higher-order cognitive processes (Mechler et al., 2022; Petrovic & Castellanos, 2016). Dysregulation of catecholaminergic neurotransmission, specifically dopamine and norepinephrine, leads to reduced signal fidelity and impaired top-down behavioural

control. These neurochemical and structural abnormalities are thought to underlie the hallmark ADHD symptoms and contribute to difficulties with attention regulation, response inhibition, and behavioural modulation.

ADHD commonly co-occurs with other psychiatric and neurodevelopmental disorders, including anxiety, depression, substance use disorders, and autism spectrum disorder (Faraone et al., 2015; Taipale et al., 2024; Craddock, 2026). These comorbidities complicate clinical management and highlight the need for individualised therapeutic strategies that address both core ADHD symptoms and secondary conditions. Functional consequences of ADHD extend beyond symptomatology to include reduced quality of life, impaired psychosocial development, and increased societal costs due to educational support needs and productivity losses (Noah & Sedky, 2025; Mechler et al., 2022).

Treatment guidelines emphasise a multimodal approach, combining pharmacological interventions with behavioural therapy, psychoeducation, and psychosocial support (Association of the Scientific Medical Societies in Germany, 2024). Pharmacotherapy remains a cornerstone due to its rapid and robust impact on core ADHD symptoms. Stimulant medications, including methylphenidate and amphetamines, are first-line treatments, demonstrating high efficacy across paediatric and adult populations (Ostinelli et al., 2025; Noah & Sedky, 2025). However, stimulants present limitations such as adverse cardiovascular effects, sleep disturbances, reduced appetite, potential for misuse, and partial response in approximately 30% of patients (Ostinelli et al., 2025; Noah & Sedky, 2025). These challenges have prompted increased interest in non-stimulant pharmacological alternatives.

Non-stimulant agents such as atomoxetine, clonidine, and guanfacine offer distinct mechanisms of action and are particularly useful in patients with stimulant contraindications, comorbid anxiety, tics, or sleep disturbances (Kawasaki et al., 2026; Mechler et al., 2022). Among these, guanfacine, a selective alpha-2A adrenergic receptor agonist, has gained attention due to its ability to enhance prefrontal cortical function, improve executive control, and reduce hyperactivity and impulsivity without the abuse potential associated with stimulants. Originally developed as an antihypertensive agent, guanfacine was repurposed for ADHD based on evidence of central nervous system effects that modulate neuronal firing patterns within the PFC (Kawasaki et al., 2026). Its prescription rates have increased, particularly in paediatric populations, reflecting its growing clinical relevance (Kawasaki et al., 2026). Despite accumulating evidence, questions remain regarding guanfacine's optimal dosing, long-term safety, and efficacy relative to other non-stimulant agents.

Methodology

This review aims to provide a comprehensive analysis of guanfacine in the treatment of ADHD, examining its neurobiological mechanisms, pharmacokinetics, clinical efficacy, tolerability, and therapeutic role in contemporary treatment strategies based on publications from years 2023-2026 available on the PubMed platform. Search words used were: guanfacine, guanfacine ADHD, ADHD treatment.

Neurobiological Mechanisms and Receptor Pharmacology

Guanfacine's therapeutic effects in ADHD are primarily mediated through selective agonism of postsynaptic alpha-2A adrenergic receptors located in the prefrontal cortex (PFC). The PFC is central to executive functioning, encompassing working memory, attention regulation, inhibitory control, planning, and emotional regulation (Petrovic & Castellanos, 2016; Mechler et al., 2022). Dysfunctional PFC activity is a core neurobiological feature of ADHD, resulting in impairments in behavioural regulation, cognitive flexibility, and goal-directed behaviour (Faraone et al., 2015).

At the cellular level, guanfacine's activation of postsynaptic alpha-2A receptors inhibits adenylate cyclase activity, leading to reduced cyclic adenosine monophosphate (cAMP) production. This cascade ultimately results in the closure of hyperpolarisation-activated cyclic nucleotide-gated (HCN) channels, which are otherwise responsible for destabilising neuronal firing (Petrovic & Castellanos, 2016; Mechler et al., 2022). By stabilising these currents, guanfacine enhances persistent firing of PFC neurons, thereby improving signal-to-noise ratios and facilitating more consistent and focused neuronal activity. This mechanism contrasts with stimulants, which increase extracellular dopamine and norepinephrine broadly, producing widespread neural effects rather than the targeted modulation of PFC circuitry (Michelini et al., 2023).

Electrophysiological studies provide further support for these mechanisms. For instance, electroencephalography (EEG) analyses demonstrate that guanfacine enhances cortical synchrony associated with spatial working memory and attentional control (Michelini et al., 2023; Michelini et al., 2023). These effects are observed both in isolation and in combination with stimulant medications, suggesting additive or

synergistic benefits in neural efficiency and cognitive performance. Importantly, these studies indicate that guanfacine selectively enhances prefrontal cortical circuits involved in executive functioning without globally increasing arousal, which may account for its relatively low abuse potential compared to stimulants.

Beyond its effects in the PFC, guanfacine also acts on brainstem structures, particularly the locus coeruleus, which is a major source of central norepinephrine. By reducing tonic firing in the locus coeruleus, guanfacine decreases sympathetic nervous system output, leading to diminished physiological arousal and anxiolytic effects (de Cássia Collaço et al., 2024). This dual action—enhancing prefrontal cortical signalling while reducing peripheral sympathetic activation—may account for the observed improvements in emotional regulation and reductions in hyperarousal in patients with ADHD, as well as its efficacy in addressing comorbid anxiety and sleep disturbances (Rocha et al., 2023; de Cássia Collaço et al., 2024).

Neuroimaging studies further corroborate guanfacine's modulatory effects on prefrontal cortical networks. Functional magnetic resonance imaging (fMRI) indicates increased activation in dorsolateral and ventrolateral PFC regions during working memory and inhibitory control tasks following guanfacine administration (Petrovic & Castellanos, 2016; Michelini et al., 2023). Additionally, improved connectivity between the PFC and subcortical structures such as the striatum and thalamus has been observed, suggesting that guanfacine enhances top-down regulatory control over motor output and emotional responses. These findings align with clinical observations of reductions in hyperactivity, impulsivity, and emotional dysregulation.

Alpha-2A receptor agonism also influences catecholaminergic tone through indirect feedback mechanisms. By enhancing prefrontal regulation over subcortical circuits, guanfacine can normalise dopamine and norepinephrine signalling patterns, thereby improving the fidelity of attentional and executive processes (Mechler et al., 2022). Unlike stimulants, which can increase catecholamine levels indiscriminately and produce secondary effects such as insomnia, appetite suppression, or cardiovascular stimulation, guanfacine's targeted mechanism minimises these off-target effects while supporting cognitive control (Ostinelli et al., 2025; Noah & Sedky, 2025).

Additional preclinical and clinical studies indicate that guanfacine's effects are dose-dependent and influenced by receptor density and individual neurobiology. Variability in response may reflect differences in alpha-2A receptor expression, PFC connectivity, and baseline catecholamine levels, underscoring the need for individualised dosing strategies and titration schedules (Voetterl et al., 2023; Michelini et al., 2023). Understanding these mechanisms not only informs clinical practice but also highlights potential avenues for biomarker-guided treatment, enabling clinicians to predict which patients are most likely to benefit from guanfacine therapy.

Pharmacokinetics and Drug Interactions

Guanfacine is available in both immediate-release and extended-release formulations, each of which has distinct pharmacokinetic characteristics that inform clinical use. Immediate-release guanfacine reaches peak plasma concentrations within 1 to 4 hours after oral administration and has a half-life of approximately 17 hours in adults, whereas the extended-release formulation achieves steady-state plasma levels over 5 to 7 days and allows for once-daily dosing (Kawasaki et al., 2026; Mechler et al., 2022). Extended-release guanfacine is generally preferred in ADHD treatment due to its stable plasma concentration, reduced peak-trough variability, and convenience for patient adherence, particularly in paediatric populations (Kawasaki et al., 2026; Baweja et al., 2024).

Guanfacine is primarily metabolised by the cytochrome P450 3A4 (CYP3A4) enzyme system in the liver. Consequently, co-administration with medications that inhibit or induce CYP3A4 can significantly alter plasma drug concentrations. For instance, potent CYP3A4 inhibitors such as ketoconazole, itraconazole, and certain macrolide antibiotics can elevate guanfacine levels, increasing the risk of hypotension, bradycardia, and sedation (Law et al., 2022; Inoue et al., 2024). Conversely, CYP3A4 inducers such as rifampin, phenytoin, and carbamazepine may reduce guanfacine efficacy by accelerating its metabolism. These interactions necessitate careful medication review, dosage adjustments, and clinical monitoring when initiating or discontinuing concomitant therapies (Law et al., 2022).

Renal excretion plays a minor role in guanfacine elimination, with less than 10% of the administered dose recovered unchanged in urine. Hepatic impairment can therefore have a substantial impact on drug exposure, while mild-to-moderate renal impairment generally has a limited effect on pharmacokinetics (Law et al., 2022). Patients with significant liver dysfunction require dose adjustments and careful monitoring, as excessive plasma concentrations can exacerbate adverse effects such as hypotension and somnolence (Doi et al., 2024).

The pharmacodynamic profile of guanfacine is closely linked to its pharmacokinetics. Sedation, hypotension, and bradycardia are dose-dependent effects that are most pronounced during the initial titration period. To mitigate these adverse effects, clinical guidelines recommend a gradual upward titration starting from low doses (e.g., 1 mg/day in children and adolescents) and increasing incrementally based on therapeutic response and tolerability (Association of the Scientific Medical Societies in Germany, 2024; Kawasaki et al., 2026). Titration schedules typically span two to four weeks, with close monitoring of cardiovascular parameters, including blood pressure and heart rate, particularly in patients with preexisting cardiac conditions.

Extended-release guanfacine's pharmacokinetic stability contributes to improved adherence and reduced adverse events compared with immediate-release formulations. By maintaining consistent plasma levels, extended-release formulations prevent fluctuations in efficacy and side effect intensity that can occur with shorter-acting preparations (Kawasaki et al., 2026). This is particularly relevant for school-aged children and adolescents, where medication peaks and troughs can impact attention, behaviour, and emotional regulation throughout the day.

Drug discontinuation requires a gradual taper rather than abrupt cessation to avoid rebound hypertension and sympathetic overactivity. The precise mechanism for rebound effects is believed to involve sudden loss of alpha-2A receptor stimulation in the PFC and brainstem, which transiently increases noradrenergic tone and sympathetic outflow (Mechler et al., 2022; Doi et al., 2024). Clinicians typically reduce the dose by 1 mg every 3 to 7 days in paediatric patients, with slower tapering recommended for individuals on higher doses or with cardiovascular comorbidities.

Guanfacine exhibits relatively low potential for pharmacokinetic interactions beyond CYP3A4 modulation. It does not significantly inhibit or induce other cytochrome P450 enzymes and does not substantially alter the metabolism of common psychotropic medications, including selective serotonin reuptake inhibitors, atomoxetine, or methylphenidate (Law et al., 2022; Kawasaki et al., 2026). This pharmacokinetic profile contributes to its safety and versatility in combination therapy, allowing clinicians to incorporate guanfacine alongside stimulants or other non-stimulant ADHD medications without major risk of adverse drug-drug interactions.

Recent investigations have also explored guanfacine's interactions with off-target physiological systems. Studies indicate minor effects on ocular parameters, such as intraocular pressure and accommodation, as well as potential influences on bone metabolism through inhibition of mesenchymal stem cell migration and osteoblast differentiation (Torun et al., 2025; Wagener et al., 2022). While these effects are generally subclinical and of limited concern in short-term therapy, they highlight the importance of ongoing research into long-term safety, particularly in paediatric populations undergoing rapid skeletal development.

Overall, guanfacine's pharmacokinetic characteristics, including metabolism, formulation differences, and interactions, provide a foundation for individualised and safe dosing strategies. Its predictable profile allows for integration into complex ADHD treatment regimens, including polypharmacy scenarios, while minimising adverse effects and optimising therapeutic outcomes. Understanding these parameters is critical for clinicians seeking to leverage guanfacine's benefits while mitigating potential risks, particularly in populations with comorbid medical or psychiatric conditions.

Clinical Efficacy

Guanfacine has demonstrated consistent efficacy in reducing core symptoms of attention-deficit/hyperactivity disorder (ADHD) across paediatric, adolescent, and adult populations. Clinical studies and meta-analyses indicate that guanfacine primarily reduces hyperactivity and impulsivity, while effects on inattention are modest but clinically meaningful when assessed over extended treatment periods (Noah & Sedky, 2025; Mechler et al., 2022). Its targeted mechanism of alpha-2A receptor agonism in the prefrontal cortex (PFC) underpins these improvements, particularly in domains related to executive function, emotional regulation, and behavioural control (Petrovic & Castellanos, 2016; Michelini et al., 2023).

Paediatric and Adolescent Populations

In children and adolescents, numerous randomised controlled trials and observational studies have reported significant reductions in ADHD symptom severity following guanfacine treatment. For example, Kawasaki et al. (2026) conducted a retrospective analysis of paediatric patients requiring early pharmacotherapy and observed that extended-release guanfacine effectively reduced hyperactivity and impulsivity, especially in those intolerant to stimulant medications. Improvements were not limited to symptom reduction but extended to enhanced academic performance, social interactions, and family functioning, reflecting real-world benefits beyond standardised rating scales.

Furthermore, guanfacine has shown efficacy in managing behavioural dysregulation and comorbid conditions commonly observed in paediatric ADHD populations. Children with concomitant sleep disturbances, anxiety, or tic disorders often derive additional therapeutic benefits from guanfacine, as its

sedative properties and central sympathetic modulation address these overlapping symptom domains (Rocha et al., 2023; de Cássia Collaço et al., 2024; Takahashi et al., 2022). For instance, case reports and clinical observations have documented improvements in sleep onset and quality, reductions in anxiety-related hyperarousal, and attenuation of tic severity, highlighting guanfacine's versatility as part of individualised treatment plans (Rocha et al., 2023; Takahashi et al., 2022).

Electrophysiological studies in paediatric populations further reinforce these clinical findings. Michelini et al. (2023) utilised electroencephalography (EEG) to assess spatial working memory and found that guanfacine, both as monotherapy and in combination with methylphenidate, enhanced cortical synchrony in prefrontal networks. These neural changes correlated with measurable improvements in attentional control, working memory, and inhibitory function, suggesting that guanfacine's effects extend beyond symptom suppression to functional neural enhancement.

Adult Populations

While most research has focused on children and adolescents, emerging evidence indicates that guanfacine also benefits adults with ADHD. Adult studies demonstrate moderate efficacy, particularly in reducing hyperactivity and impulsivity, though effect sizes tend to be smaller compared with stimulants (Ostinelli et al., 2025; Noah & Sedky, 2025). Guanfacine is particularly valuable for adults with contraindications to stimulant therapy, such as a history of substance use disorder, cardiovascular risk, or intolerable stimulant-related side effects.

Taipale et al. (2024) examined work disability and mental health outcomes in adults receiving ADHD pharmacotherapy and found that non-stimulant medications, including guanfacine, contributed to reduced work absenteeism and improved psychosocial functioning. Although the magnitude of symptom reduction may be less pronounced than with stimulants, guanfacine's favourable tolerability profile and low abuse potential make it a practical and sustainable option for long-term management.

Combination Therapy and Residual Symptoms

In clinical practice, guanfacine is frequently employed as adjunctive therapy to stimulant medications. Combination therapy may enhance symptom control by targeting residual deficits that persist despite stimulant treatment, such as emotional dysregulation, insomnia, or impulsive behaviours (Michelini et al., 2023; Miyazaki & Uchiyama, 2023). Evidence suggests that guanfacine's selective modulation of prefrontal cortical circuits complements the broader catecholaminergic enhancement provided by stimulants, leading to additive benefits without substantial increases in adverse effects.

For example, Michelini et al. (2023) reported that children receiving combined guanfacine and methylphenidate therapy exhibited greater improvements in executive function and working memory than those receiving either medication alone. These findings suggest that guanfacine can address domains of dysfunction inadequately targeted by stimulants, highlighting its role in a nuanced, multimodal pharmacological strategy.

Comparative Effectiveness

Comparisons with other non-stimulant treatments further elucidate guanfacine's clinical utility. Atomoxetine, a selective norepinephrine reuptake inhibitor, has demonstrated robust improvements in attention but may be associated with gastrointestinal disturbances, mood changes, and delayed onset of action (Noah & Sedky, 2025; Mechler et al., 2022). Clonidine, another alpha-2 adrenergic agonist, is less selective for alpha-2A receptors and often produces pronounced sedation and cardiovascular effects, limiting its long-term utility (Mechler et al., 2022). Guanfacine's selectivity for alpha-2A receptors allows for targeted enhancement of prefrontal cortical function with a lower incidence of sedation and cardiovascular compromise, making it a favourable choice among non-stimulant therapies (Doi et al., 2024).

Effects on Comorbid Conditions

A notable advantage of guanfacine lies in its efficacy for ADHD with comorbid conditions. Its central sympathetic modulation and sedative properties are particularly beneficial in addressing anxiety, sleep disturbances, and emotional dysregulation (Rocha et al., 2023; de Cássia Collaço et al., 2024). Moreover, guanfacine has been used successfully to manage tic disorders in children and adolescents, demonstrating reductions in tic severity while simultaneously improving core ADHD symptoms (Mechler et al., 2022). In patients with autism spectrum disorder and co-occurring ADHD symptoms, guanfacine has been associated with improvements in hyperactivity and impulsivity, although the evidence remains preliminary and warrants further controlled studies (Craddock, 2026).

Functional Outcomes

Beyond symptom reduction, guanfacine has been linked to improvements in functional outcomes, including academic performance, social engagement, and family interactions. Baweja et al. (2024) reported that preschool and school-aged children receiving guanfacine demonstrated enhanced classroom behaviour, increased task completion, and improved parent-rated executive functioning. Similarly, in adults, Taipale et al. (2024) found reductions in work disability and improved social functioning, suggesting that guanfacine contributes meaningfully to quality-of-life measures across the lifespan.

Safety And Tolerability

Guanfacine is generally well tolerated, with a safety profile that differs substantially from stimulant medications. Its non-stimulant mechanism, centred on selective alpha-2A adrenergic receptor agonism, confers a lower risk of abuse and dependence, making it particularly suitable for patients with a history of substance use disorders or those at risk for stimulant misuse (Noah & Sedky, 2025; Kawasaki et al., 2026). However, as with any pharmacological intervention, a spectrum of adverse effects has been observed, ranging from mild sedation to cardiovascular complications, necessitating careful dose titration and ongoing clinical monitoring.

Sedation and Somnolence

Sedation is the most frequently reported adverse effect of guanfacine. This effect is dose-dependent and often emerges during the initial phase of treatment, particularly when initiating extended-release formulations or escalating doses too rapidly (Doi et al., 2024). Somnolence may manifest as daytime drowsiness, fatigue, or reduced alertness, and can interfere with school, work, or daily activities. Although sedation typically diminishes over several weeks of continued therapy, early occurrences can lead to premature discontinuation, underscoring the importance of gradual titration and patient counselling (Doi et al., 2024; Rocha et al., 2023).

Clinical strategies to mitigate sedation include administering the medication at bedtime, starting with low doses, and adjusting titration schedules according to individual tolerability. In paediatric populations, caregivers should be advised to monitor morning alertness and daytime sleepiness, as these effects can impact learning and social functioning. Gradual dose increases, spaced over one to two weeks, are recommended to allow adaptation of central nervous system processes and minimise abrupt changes in arousal (Kawasaki et al., 2026).

Cardiovascular Effects

Guanfacine's pharmacodynamic action on central alpha-2A receptors also influences cardiovascular function. By reducing sympathetic outflow from the brainstem, guanfacine can lower blood pressure and heart rate, resulting in hypotension or bradycardia in susceptible individuals (Inoue et al., 2024). Most cases are mild, asymptomatic, and transient, but clinically significant hypotension or bradyarrhythmia may occur, particularly in patients with pre-existing cardiovascular conditions, concurrent antihypertensive therapy, or high-dose regimens.

Rare instances of QT interval prolongation have been reported, particularly when plasma concentrations exceed therapeutic levels (Inoue et al., 2024). While these events are uncommon, they highlight the need for careful cardiac assessment in patients with known arrhythmias, congenital long QT syndrome, or concurrent use of other QT-prolonging medications. Baseline cardiovascular evaluation, including blood pressure and heart rate measurement, is recommended before initiating therapy, with ongoing monitoring during dose titration (Law et al., 2022; Inoue et al., 2024).

Gastrointestinal and Neurological Effects

Other adverse effects are generally mild and include headache, dizziness, and gastrointestinal disturbances such as nausea or abdominal discomfort (Mechler et al., 2022; Noah & Sedky, 2025). Neurological symptoms beyond sedation are rare but may include transient fatigue, irritability, or mild dizziness. These effects are typically self-limiting, resolving with continued therapy or minor adjustments in dosing.

Emerging evidence has also examined the potential impact of guanfacine on ocular and musculoskeletal parameters. Torun et al. (2025) reported minor changes in intraocular pressure and ocular motility in paediatric and adolescent patients, although no clinically significant visual impairment was observed. Similarly, Wagener et al. (2022) identified effects on bone cell differentiation and mesenchymal stem cell migration in preclinical models, raising questions about long-term skeletal health, particularly in growing children. While these findings are preliminary, they underscore the importance of monitoring growth and musculoskeletal development during prolonged therapy.

Discontinuation and Withdrawal Considerations

Abrupt discontinuation of guanfacine can result in rebound hypertension, irritability, or exacerbation of ADHD symptoms, reflecting physiological adaptation to chronic alpha-2A receptor stimulation (Noah & Sedky, 2025; Doi et al., 2024). Therefore, tapering is strongly recommended when discontinuing therapy, typically over one to two weeks, depending on dosage and treatment duration. Tapering protocols reduce the risk of cardiovascular and behavioural rebound phenomena and ensure a safer transition for patients who discontinue therapy due to adverse effects or treatment changes.

Drug–Drug Interactions

Guanfacine is metabolised primarily via the cytochrome P450 3A4 (CYP3A4) enzyme system, introducing the potential for clinically relevant drug–drug interactions (Law et al., 2022). Concomitant use of CYP3A4 inhibitors, such as certain antifungal agents or macrolide antibiotics, can increase plasma guanfacine levels, potentially intensifying sedation or cardiovascular effects. Conversely, CYP3A4 inducers, including some anticonvulsants and rifampin, may lower therapeutic concentrations, reducing efficacy. Clinicians should conduct thorough medication reviews and adjust dosing accordingly, particularly in populations with polypharmacy, including adolescents on psychotropic regimens or adults with comorbid medical conditions (Law et al., 2022; Kawasaki et al., 2026).

Tolerability in Special Populations

Special populations, including preschool children, adolescents with comorbidities, and adults with cardiovascular risk factors, require particular attention to safety and tolerability. Baweja et al. (2024) highlighted that preschool children may be more sensitive to sedative effects, necessitating lower initial doses and careful monitoring. In patients with ADHD and comorbid anxiety, depression, or sleep disorders, guanfacine's sedative and anxiolytic properties can be therapeutically advantageous but may also exacerbate daytime sleepiness or impair cognitive alertness if not titrated appropriately (de Cássia Collaço et al., 2024; Rocha et al., 2023).

Adults with cardiovascular comorbidities or on antihypertensive therapy require careful baseline evaluation and ongoing monitoring, with particular attention to orthostatic hypotension, bradycardia, and electrocardiographic parameters when indicated. Individualised dosing, patient education, and interdisciplinary collaboration are key strategies to optimise tolerability while minimising adverse events (Inoue et al., 2024; Law et al., 2022).

Long-Term Outcomes and Functional Impact

Understanding the long-term outcomes of guanfacine therapy is crucial for assessing its role in sustained ADHD management, particularly given that ADHD is a chronic neurodevelopmental disorder with functional implications extending into adulthood. While short-term studies consistently demonstrate reductions in core ADHD symptoms, evidence regarding the durability of these benefits, the impact on psychosocial functioning, and long-term safety remains limited but increasingly informative.

Sustained Symptom Control

Evidence from longitudinal observational studies indicates that guanfacine can provide sustained improvements in hyperactivity, impulsivity, and, to a lesser extent, inattention over months to years of continuous therapy. In paediatric populations, improvements in classroom behaviour, task completion, and social interactions have been documented in both open-label and extended follow-up studies (Mechler et al., 2022; Kawasaki et al., 2026). These findings suggest that guanfacine's mechanism of enhancing prefrontal cortical regulation continues to confer cognitive and behavioural benefits beyond the initial treatment phase.

In adults, while randomised controlled trials are sparse, available data indicate moderate, yet clinically meaningful, symptom reduction (Ostinelli et al., 2025; Noah & Sedky, 2025). Adults with comorbid anxiety, sleep disturbances, or substance use risk factors appear to benefit from guanfacine's dual action on prefrontal circuits and central sympathetic tone, leading to improvements in emotional regulation and arousal control (de Cássia Collaço et al., 2024; Michelini et al., 2023). Moreover, adjunctive use with stimulants has shown promise in addressing residual symptoms, with long-term combination therapy associated with enhanced overall symptom control compared to monotherapy (Michelini et al., 2023; Miyazaki & Uchiyama, 2023).

Psychosocial and Functional Outcomes

Beyond symptom reduction, guanfacine's effects on functional outcomes, including academic performance, occupational stability, and interpersonal relationships, have been explored. In school-aged children, improved behavioural regulation translates to increased engagement in classroom activities, better adherence to instructions, and reduced disruptive behaviour, which in turn positively influences academic achievement (Kawasaki et al., 2026; Rocha et al., 2023). Similarly, reductions in impulsivity and hyperactivity facilitate social interactions, enhancing peer relationships and reducing the risk of social exclusion or bullying.

In adults, Taipale et al. (2024) demonstrated that ADHD pharmacotherapy, including non-stimulant agents such as guanfacine, is associated with reduced work disability and improved mental health outcomes. Although this study encompassed a broader population, the findings underscore the potential of guanfacine to mitigate long-term functional impairments when incorporated into a comprehensive treatment plan. These benefits are particularly pronounced for individuals with comorbid anxiety, sleep disturbances, or tic disorders, highlighting the importance of personalised approaches that consider both symptom control and functional improvement (de Cássia Collaço et al., 2024).

Sleep and Emotional Regulation

Sleep disturbances are prevalent in individuals with ADHD and can exacerbate cognitive and behavioural difficulties. Guanfacine's sedative and arousal-modulating effects contribute to improvements in sleep onset latency and overall sleep quality, particularly in children with delayed sleep-phase or insomnia (Rocha et al., 2023; Takahashi et al., 2022). Improved sleep, in turn, enhances daytime functioning, emotional regulation, and attentional control, creating a synergistic effect that supports long-term adaptive functioning.

Emotional dysregulation, often characterised by irritability, mood swings, and impulsive aggression, is increasingly recognised as a critical contributor to functional impairment in ADHD (Petrovic & Castellanos, 2016). Guanfacine's modulation of prefrontal cortical circuits facilitates inhibitory control and top-down regulation of emotional responses, which may reduce aggressive outbursts, improve frustration tolerance, and enhance social interactions (Michelini et al., 2023; Noah & Sedky, 2025). These effects, though subtle compared to core symptom reduction, are highly relevant to long-term psychosocial outcomes.

Growth and Developmental Considerations

In paediatric populations, long-term pharmacotherapy requires attention to potential effects on growth and development. While guanfacine does not exhibit the appetite-suppressing properties commonly associated with stimulant medications, preclinical studies have raised concerns regarding skeletal development, including alterations in bone cell differentiation and mesenchymal stem cell migration (Wagener et al., 2022). Clinical significance remains uncertain, but routine monitoring of growth parameters, including height, weight, and pubertal development, is recommended during extended therapy.

Additionally, ocular parameters such as intraocular pressure and ocular motility have shown minor changes in paediatric patients treated with guanfacine, though no clinically significant visual deficits have been reported (Torun et al., 2025). These findings highlight the need for ongoing surveillance of developmental milestones and physiological outcomes during prolonged treatment courses.

Long-Term Safety

Long-term safety remains an important consideration. Cardiovascular monitoring is particularly relevant, given the potential for bradycardia, hypotension, and rare QT interval prolongation (Inoue et al., 2024). While most adverse events decrease over time with gradual dose titration, continued vigilance is essential to identify delayed or cumulative effects. Furthermore, sedation-related functional impairments may persist in some individuals, emphasising the need for individualised dosing and careful scheduling to minimise interference with daily activities (Doi et al., 2024).

Limitations of Current Evidence

While guanfacine has emerged as a valuable non-stimulant pharmacotherapy for ADHD, the current body of evidence presents several limitations that must be considered when interpreting clinical efficacy, safety, and long-term outcomes. These limitations reflect methodological constraints, gaps in population representation, and the heterogeneity of ADHD itself, highlighting areas for future research and clinical refinement.

Methodological Constraints

A significant limitation of current studies on guanfacine is their reliance on short-term clinical trials. Most randomised controlled trials (RCTs) assess outcomes over periods of 6 to 12 weeks, which may capture acute symptom reduction but cannot fully elucidate long-term effectiveness, functional improvements, or the persistence of adverse effects (Mechler et al., 2022; Kawasaki et al., 2026). The predominance of paediatric-focused studies further limits generalizability to adolescents and adults, populations in which ADHD often persists with distinct functional impairments and comorbidities (Ostinelli et al., 2025; Noah & Sedky, 2025).

Many trials also employ relatively small sample sizes, reducing statistical power and increasing susceptibility to bias. Variability in outcome measures—ranging from clinician-rated scales such as the ADHD Rating Scale-IV to parent- or teacher-reported metrics—introduces inconsistencies in reported efficacy and makes cross-study comparisons challenging. Furthermore, heterogeneity in titration protocols, dosing schedules, and concomitant therapies complicates the interpretation of findings and may contribute to variability in reported treatment responses (Michelini et al., 2023; Miyazaki & Uchiyama, 2023).

Population Representation

Current research disproportionately emphasises children aged 6–12 years, with limited inclusion of adolescents and adults, as well as underrepresented groups such as females, ethnic minorities, and individuals with complex comorbidities (Craddock, 2026; Mechler et al., 2022). ADHD manifests differently across developmental stages, genders, and cultural contexts, influencing both symptom presentation and response to

pharmacotherapy. For example, hyperactivity may decrease with age, whereas inattention and executive dysfunction often persist, potentially altering treatment priorities and efficacy outcomes in older populations (Noah & Sedky, 2025; Taipale et al., 2024).

Additionally, comorbid conditions—including anxiety, mood disorders, tic disorders, and substance use disorders—are frequently exclusion criteria in RCTs, limiting external validity. Yet, these comorbidities are common in real-world clinical practice and may significantly influence treatment response, tolerability, and functional outcomes. Observational studies and real-world evidence indicate that guanfacine can provide dual benefits in patients with comorbid anxiety or sleep disturbances, but systematic investigations are limited, particularly in adult populations (de Cássia Collaço et al., 2024; Rocha et al., 2023).

Long-Term Safety and Functional Outcomes

Long-term safety remains an area of uncertainty. While guanfacine is generally well tolerated, the potential for cardiovascular effects, sedation, and rare QT prolongation necessitates ongoing monitoring (Inoue et al., 2024; Doi et al., 2024). Paediatric studies suggest minimal impact on growth, but preclinical data indicate possible effects on bone metabolism, raising questions regarding skeletal development during prolonged treatment (Wagener et al., 2022). Similarly, ocular parameter changes have been noted, though their functional significance is not well established (Torun et al., 2025).

Functional outcomes—including academic achievement, occupational performance, and social functioning—are frequently secondary endpoints or assessed indirectly. There is a lack of longitudinal, standardised assessments that integrate patient-reported outcomes and objective measures of quality of life. Without robust data linking symptom reduction to meaningful real-world improvements, it remains challenging to fully evaluate guanfacine's long-term clinical utility (Taipale et al., 2024; Voetterl et al., 2023).

Comparative Effectiveness

Head-to-head comparisons of guanfacine with other non-stimulant and stimulant medications are limited. While network meta-analyses and indirect comparisons provide some insights, the absence of direct RCTs restricts definitive conclusions regarding relative efficacy, tolerability, and functional benefits (Ostinelli et al., 2025; Mechler et al., 2022). Differences in mechanism of action, receptor selectivity, and pharmacokinetics suggest unique therapeutic profiles, but the lack of comparative data limits evidence-based selection of the most appropriate agent for individual patients, particularly in complex clinical scenarios involving comorbidities or prior treatment failures (Kawasaki et al., 2026; Noah & Sedky, 2025).

Future Research Directions

Addressing these limitations will require comprehensive, methodologically rigorous investigations. First, long-term, multi-centre RCTs and large-scale observational studies should examine guanfacine's sustained efficacy, safety, and functional outcomes across paediatric, adolescent, and adult populations. Standardised metrics of academic, occupational, and social functioning, as well as patient-reported quality-of-life outcomes, should be incorporated to ensure findings translate to meaningful real-world benefits.

Second, research should emphasise underrepresented populations, including females, ethnic minorities, and individuals with multiple comorbidities. Stratified analyses based on age, gender, and comorbid conditions could clarify differential treatment responses and inform more personalised approaches to ADHD pharmacotherapy (Craddock, 2026; de Cássia Collaço et al., 2024).

Third, biomarker-driven studies offer a promising avenue for personalised treatment selection. Neuroimaging, electrophysiological, and genetic markers have shown potential in predicting response to stimulants and non-stimulants, including guanfacine (Michelini et al., 2023; Voetterl et al., 2023). Incorporating these biomarkers into clinical trials could enhance treatment precision, reduce trial-and-error prescribing, and optimise functional outcomes.

Fourth, combination therapy and sequencing strategies warrant further exploration. Evidence suggests that adjunctive guanfacine can enhance residual symptom control and mitigate stimulant-related side effects, yet optimal sequencing, dosing, and duration strategies remain undefined (Michelini et al., 2023; Miyazaki & Uchiyama, 2023). Investigating these approaches in both paediatric and adult populations could inform practical clinical guidelines and maximise therapeutic benefit.

Finally, mechanistic research into guanfacine's effects on prefrontal cortical circuits, autonomic regulation, and downstream functional outcomes may elucidate additional therapeutic pathways. Understanding the interaction between guanfacine, environmental factors, and neurodevelopmental trajectories could enable early intervention strategies, particularly in patients with high-risk profiles or early-onset ADHD (Petrovic & Castellanos, 2016; Kawasaki et al., 2026).

Conclusions

Guanfacine improves ADHD symptomatology through a combination of selective prefrontal cortical modulation and reduction of sympathetic outflow. Its action on postsynaptic alpha-2A receptors stabilises neuronal firing, enhances working memory, and improves inhibitory control, while its influence on brainstem norepinephrine activity promotes anxiolysis and sleep regulation. These mechanisms underpin its efficacy in reducing hyperactivity and impulsivity, complementing or, in some cases, substituting for stimulant medications in individualised treatment plans. Its benefits extend to paediatric, adolescent, and adult populations, both as monotherapy and in combination with stimulants. Furthermore, its effectiveness in managing comorbid conditions, functional impairments, and residual symptoms underscores its versatility as a key component of individualised ADHD pharmacotherapy.

Pharmacokinetically, the availability of extended-release formulations allows for once-daily dosing, promoting adherence and stabilising plasma concentrations to optimise therapeutic effects. Its metabolism via the CYP3A4 pathway necessitates careful consideration of potential drug–drug interactions, particularly in polypharmacy contexts or in patients receiving inhibitors or inducers of this enzyme system (Law et al., 2022). Dose titration remains essential to mitigate adverse effects, particularly sedation, hypotension, and bradycardia, which are generally dose-dependent and most pronounced during treatment initiation. Cardiovascular monitoring is recommended, especially for patients with preexisting conditions or when guanfacine is combined with other agents affecting cardiac function. Rarely, QT interval prolongation may occur, necessitating vigilance in high-risk populations.

Guanfacine also demonstrates a generally favourable safety profile relative to stimulant medications, particularly regarding abuse potential and mood-related adverse effects. Sedation, hypotension, and bradycardia remain the most common treatment-limiting effects, whereas serious cardiovascular or neurological complications are rare. Careful dose titration, patient and caregiver education, monitoring of cardiovascular and growth parameters, and awareness of drug interactions are essential to maximise safety and tolerability. By implementing these strategies, clinicians can optimise treatment outcomes while minimising adverse effects, reinforcing guanfacine's role as a safe and effective option in both paediatric and adult ADHD pharmacotherapy.

Long-term treatment with guanfacine shows promise in maintaining symptom reduction and enhancing functional outcomes in individuals with ADHD. Improvements in hyperactivity, impulsivity, emotional regulation, sleep quality, and social functioning underscore the medication's potential for holistic benefits beyond core symptom control. While preliminary data support sustained efficacy and tolerability, gaps remain in understanding long-term safety, adult outcomes, and comparative effectiveness. Continued research is essential to guide individualised treatment strategies and optimise functional outcomes across developmental stages and clinical contexts.

Despite its promise, the evidence base for guanfacine is constrained by several limitations. Paediatric populations dominate clinical research, leaving adolescents and adults underrepresented. Short-term RCTs constitute the majority of studies, limiting understanding of sustained efficacy and long-term safety. Variability in study design, dosing protocols, outcome measures, and inclusion criteria reduces comparability across trials and underscores the need for standardised research methodologies. Furthermore, head-to-head trials comparing guanfacine with other non-stimulants or stimulants are sparse, restricting the ability to draw definitive conclusions regarding comparative efficacy, tolerability, and functional impact.

REFERENCES

1. Ostinelli, E. G., Schulze, M., Zangani, C., Farhat, L. C., Tomlinson, A., Del Giovane, C., Chamberlain, S. R., Philipsen, A., Young, S., Cowen, P. J., Bilbow, A., Cipriani, A., & Cortese, S. (2025). Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: A systematic review and component network meta-analysis. *The Lancet Psychiatry, 12*(1), 32–43. https://doi.org/10.1016/S2215-0366(24)00360-2
2. Noah, A. A., & Sedky, H. E. (2025). New frontiers in pharmacological treatment of attention-deficit hyperactivity disorder. *Naunyn-Schmiedeberg's Archives of Pharmacology, 398*(11), 15025–15035. https://doi.org/10.1007/s00210-025-04328-z
3. Taipale, H., Bergström, J., Gèmes, K., Tanskanen, A., Ekselius, L., Mittendorfer-Rutz, E., & Helgesson, M. (2024). Attention-deficit/hyperactivity disorder medications and work disability and mental health outcomes. *JAMA Network Open, 7*(3), Article e242859. https://doi.org/10.1001/jamanetworkopen.2024.2859
4. Kawasaki, Y., Suzuki, Y., Miyazaki, K., Suzuki, N., Hoshina, M., Kato, A., Morita, H., & Go, H. (2026). A retrospective single-center study on the characteristics of children with attention-deficit hyperactivity disorder requiring early drug therapy from 2013 to 2022 and changes in treatment over time. *Fukushima Journal of Medical Science, 72*(1), 31–40. https://doi.org/10.5387/fms.25-00016
5. Mechler, K., Banaschewski, T., Hohmann, S., & Häge, A. (2022). Evidence-based pharmacological treatment options for ADHD in children and adolescents. *Pharmacology & Therapeutics, 230*, Article 107940.
6. American Psychiatric Association. (2022). *Diagnostic and statistical manual of mental disorders* (5th ed., text rev.). American Psychiatric Association Publishing.
7. Petrovic, P., & Castellanos, F. X. (2016). Top-down dysregulation—from ADHD to emotional instability. *Frontiers in Behavioral Neuroscience, 10*, Article 70. https://doi.org/10.3389/fnbeh.2016.00070
8. Faraone, S. V., Asherson, P., Banaschewski, T., Biederman, J., Buitelaar, J. K., Ramos-Quiroga, J. A., Rohde, L. A., Sonuga-Barke, E. J., Tannock, R., & Franke, B. (2015). Attention-deficit/hyperactivity disorder. *Nature Reviews Disease Primers, 1*, Article 15020. https://doi.org/10.1038/nrdp.2015.20
9. Craddock, E. (2026). Navigating residual diagnostic categories: The lived experiences of women diagnosed with autism and ADHD in adulthood. *Health, 30*(2), 235–257. https://doi.org/10.1177/13634593251336163
10. Association of the Scientific Medical Societies in Germany. (2024). *German S3 guideline "ADHD in children, adolescents and adults" [Langfassung der interdisziplinären evidenz-und konsensbasierten (S3) Leitlinie "Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Kindes-, Jugend-und Erwachsenenalter"-AWMF-Registernummer 028-045]*.
11. Doi, K., Sogawa, R., Eguchi, Y., Matsuo, M., & Shimanoe, C. (2024). Association between early guanfacine discontinuation and somnolence for attention-deficit/hyperactivity disorder. *Biological & Pharmaceutical Bulletin, 47*(6), 1204–1208. https://doi.org/10.1248/bpb.b24-00147
12. de Cássia Collaço, R., Lammens, M., Blevins, C., Rodgers, K., Gurau, A., Yamauchi, S., Kim, C., Forrester, J., Liu, E., Ha, J., Mei, Y., Boehm, C., Wohler, E., Sobreira, N., Rowe, P. C., Valle, D., Brock, M. V., & Bosmans, F. (2024). Anxiety and dysautonomia symptoms in patients with a NaV1.7 mutation and the potential benefits of low-dose short-acting guanfacine. *Clinical Autonomic Research, 34*(1), 191–201. https://doi.org/10.1007/s10286-023-01004-1
13. Michelini, G., Lenartowicz, A., Diaz-Fong, J. P., Bilder, R. M., McGough, J. J., McCracken, J. T., & Loo, S. K. (2023). Methylphenidate, guanfacine, and combined treatment effects on electroencephalography correlates of spatial working memory in attention-deficit/hyperactivity disorder. *Journal of the American Academy of Child & Adolescent Psychiatry, 62*(1), 37–47. https://doi.org/10.1016/j.jaac.2022.06.017
14. Inoue, F., Okazaki, Y., Kashiwa, K., Ichiba, T., & Namera, A. (2024). QT-interval prolongation associated with supratherapeutic guanfacine concentration: A case report. *Journal of Medical Toxicology, 20*(2), 218–221. https://doi.org/10.1007/s13181-023-00986-8
15. Michelini, G., Lenartowicz, A., Vera, J. D., Bilder, R. M., McGough, J. J., McCracken, J. T., & Loo, S. K. (2023). Electrophysiological and clinical predictors of methylphenidate, guanfacine, and combined treatment outcomes in children with attention-deficit/hyperactivity disorder. *Journal of the American Academy of Child & Adolescent Psychiatry, 62*(4), 415–426. https://doi.org/10.1016/j.jaac.2022.08.001
16. Torun, I. M., Vatansever Pinar, Z., & İlhan, Ş. (2025). The effect of guanfacine treatment on ocular parameters in pediatric and adolescents patients with attention-deficit/hyperactivity disorder. *BMC Ophthalmology, 25*(1), Article 56. https://doi.org/10.1186/s12886-025-03886-3
17. Miyazaki, K., & Uchiyama, M. (2023). An adolescent boy with kleptomania and attention-deficit hyperactivity disorder treated with methylphenidate and guanfacine: A case report. *Neuropsychopharmacology Reports, 43*(4), 650–653. https://doi.org/10.1002/npr2.12394
18. Rocha, N. S., Correa, R. D. E. S. A., Dias, A. C. M., & Bueno, C. D. F. (2023). Association between sleep pattern and pharmacological treatment in children with attention deficit disorder with hyperactivity: A systematic review. *Revista Paulista de Pediatria, 41*, Article e2022065. https://doi.org/10.1590/1984-0462/2023/41/2022065

19. Baweja, R., Baweja, R., Weidlich, H., Nyland, J. E., Waschbusch, D. A., & Waxmonsky, J. G. (2024). Treatment utilization pattern of preschool children with attention-deficit/hyperactivity disorder. *Journal of Attention Disorders, 28*(5), 708–721. https://doi.org/10.1177/10870547231215287
20. Voetterl, H., van Wingen, G., Michelini, G., Griffiths, K. R., Gordon, E., DeBeus, R., Korgaonkar, M. S., Loo, S. K., Palmer, D., Breteler, R., Denys, D., Arnold, L. E., du Jour, P., van Ruth, R., Jansen, J., van Dijk, H., & Arns, M. (2023). Brainmarker-I differentially predicts remission to various attention-deficit/hyperactivity disorder treatments: A discovery, transfer, and blinded validation study. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 8*(1), 52–60. https://doi.org/10.1016/j.bpsc.2022.02.007
21. Mechler, K., Banaschewski, T., Hohmann, S., & Häge, A. (2022). Evidence-based pharmacological treatment options for ADHD in children and adolescents. *Pharmacology & Therapeutics, 230*, Article 107940. https://doi.org/10.1016/j.pharmthera.2021.107940
22. Takahashi, Y., Mikami, K., Kimoto, K., Onishi, Y., Yamamoto, K., & Matsumoto, H. (2022). A case of nocturnal enuresis associated with attention-deficit/hyperactivity disorder successfully treated with guanfacine monotherapy. *The Tokai Journal of Experimental and Clinical Medicine, 47*(2), 72–74.
23. Wagener, N., Lehmann, W., Weiser, L., Jäckle, K., Di Fazio, P., Schilling, A. F., & Böker, K. O. (2022). Psychostimulants modafinil, atomoxetine and guanfacine impair bone cell differentiation and MSC migration. *International Journal of Molecular Sciences, 23*(18), Article 10257. https://doi.org/10.3390/ijms231810257
24. Galvez-Contreras, A. Y., Vargas-de la Cruz, I., Beltran-Navarro, B., Gonzalez-Castaneda, R. E., & Gonzalez-Perez, O. (2022). Therapeutic approaches for ADHD by developmental stage and clinical presentation. *International Journal of Environmental Research and Public Health, 19*(19), Article 12880. https://doi.org/10.3390/ijerph191912880
25. Pan, P. Y., Jonsson, U., Şahpazoğlu Çakmak, S. S., Häge, A., Hohmann, S., Nobel Norrman, H., Buitelaar, J. K., Banaschewski, T., Cortese, S., Coghill, D., & Bölte, S. (2022). Headache in ADHD as comorbidity and a side effect of medications: A systematic review and meta-analysis. *Psychological Medicine, 52*(1), 14–25. https://doi.org/10.1017/S0033291721004141
26. Law, R., Lewis, D., Hain, D., Daut, R., DelBello, M. P., Frazier, J. A., Newcorn, J. H., Nurmi, E., Cogan, E. S., Wagner, S., Johnson, H., & Lanchbury, J. (2022). Characterisation of seven medications approved for attention-deficit/hyperactivity disorder using in vitro models of hepatic metabolism. *Xenobiotica, 52*(7), 676–686. https://doi.org/10.1080/00498254.2022.2141151
27. Kawabe, K., Horiuchi, F., Matsumoto, Y., Inoue, S., Okazawa, M., Hosokawa, R., Nakachi, K., Soga, J., & Ueno, S. I. (2024). Practical clinical guidelines and pharmacological treatment for attention-deficit hyperactivity disorder in Asia. *Neuropsychopharmacology Reports, 44*(1), 29–33. https://doi.org/10.1002/npr2.12381